FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine, more specifically to pharmacology, and concerns agents attenuating postinfarction myocardial remodelling. Disclosed is the use of n-tyrosol (n-oxyphenyl-β-ethanol, 4-(2-hydroxyethyl)phenol) as an agent relieving postinfarction myocardial remodelling.
EFFECT: using the invention enables reducing postinfarction myocardial remodelling effectively.
1 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT RELIEVING POSTINFARCTION MYOCARDIAL REMODELING | 2020 |
|
RU2740895C1 |
| TRANSLATIONAL MODEL OF CHRONIC HEART FAILURE: THE METHOD AND CRITERIA OF FORMATION ASSESSMENT | 2018 |
|
RU2744681C1 |
| AGENT IMPROVING CARDIAC RESISTANCE TO ISCHEMIC AND FOLLOWING REPERFUSION INJURIES | 2012 |
|
RU2488404C1 |
| ANTIISHEMIC AGENT | 2008 |
|
RU2384327C1 |
| METHOD OF PREDICTING POST-INFARCTION REMODELLING OF LEFT VENTRICLE MYOCARDIUM IN PATINETS WITH MYOCARDIAL INFARCTION | 2011 |
|
RU2464936C1 |
| METHOD FOR ASSESSING THE PROBABILITY OF DEVELOPING UNFAVORABLE HEART LEFT VENTRICULAR REMODELING IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION | 2021 |
|
RU2770285C1 |
| AGENT POSSESSING ENDOTHELIUM PROTECTIVE ACTIVITY | 2014 |
|
RU2563622C1 |
| METHOD FOR CARRYING OUT EXPERIMENTAL MYOCARDIAL INFARCTION THERAPY | 2005 |
|
RU2288738C2 |
| METHOD FOR PREDICTION OF RISK OF UNFAVOURABLE CARDIOVASCULAR EVENTS IN PATIENTS SUFFERING ISCHEMIC HEART DISEASE WITH ISCHEMIC AND/OR POSTINFARCTION MYOCARDIAL DYSFUNCTION ACCOMPANYING CHRONIC CARDIAL INSUFFICIENCY | 2014 |
|
RU2568577C1 |
| AGENT WITH CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2791641C2 |
